Metformin Medical Valley (Metformin Hydrochloride)

Metformin acts primarily by activating AMP‑activated protein kinase (AMPK), which suppresses hepatic gluconeogenesis, decreases intestinal glucose absorption, and enhances peripheral insulin sensitivity. These actions collectively lower fasting and post‑prandial blood‑glucose concentrations.

The dosage of Metformin Medical Valley is individualized by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength, frequency, and titration schedule.

The safety of Metformin in pregnancy and lactation is not fully established. It may be used during pregnancy only when the potential benefit outweighs the potential risk to the fetus, and breastfeeding mothers should consult their healthcare provider before use.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metformin is often preferred as first‑line therapy for type 2 diabetes because it is weight‑neutral, has a low risk of hypoglycemia, and offers cardiovascular benefits. Compared with sulfonylureas or insulin, it does not cause weight gain and has a different safety profile, making it suitable for many patients.

Metformin Medical Valley should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Metformin Medical Valley is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, hepatic disease, or conditions causing hypoxia. Prompt medical attention is required if symptoms such as unexplained fatigue, muscle pain, or rapid breathing develop.

Metformin is contraindicated in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, and in patients receiving iodinated contrast agents for imaging studies without appropriate renal monitoring.